廣生堂(300436.SZ):成為匹伐他汀鈣片上市許可持有人
格隆匯6月30日丨廣生堂(300436.SZ)公吿,近日,公司收到國家藥品監督管理局下發的關於匹伐他汀鈣片的《藥品補充申請批准通知書》,同意公司成為上述藥品(規格:4mg)上市許可持有人,進一步豐富了公司心血管領域的產品線佈局,將為公司打造新的利潤增長點。
匹伐他汀鈣主要用於治療高膽固醇血癥、家族性高膽固醇血癥,屬於第三代他汀類藥物。根據米內網數據,2020年匹伐他汀鈣中國總銷售額超過21億元,是權威指南推薦的一線調脂用藥,已列入國家醫保目錄。
本次成為匹伐他汀鈣片上市許可持有人,進一步豐富了公司心血管領域的產品線佈局,為公司提供新的利潤增長點。公司將以藥品上市許可持有人制度為契機,積極儲備有發展潛力的藥品品種,不斷豐富公司產品線,以仿哺創,助力公司創新轉型發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.